<DOC>
	<DOCNO>NCT02514512</DOCNO>
	<brief_summary>A research study new technology adjustment radiotherapy beam account movement lung tumours patient breathes radiotherapy .</brief_summary>
	<brief_title>Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator ( MLC ) Adaptation And Radiofrequency Tracking</brief_title>
	<detailed_description>Twenty patient 18 year age undergoing Stereotactic Body Radiotherapy ( SBRT ) Northern Sydney Cancer Centre lung cancer receive new treatment . Participants physically able undergo aspect treatment intellectually able provide write informed consent complete questionnaire . Beacons implant patient ' lung allow Multi Leaf Collimator ( MLC ) track equipment follow precisely movement lung . The difference ability track tumour movement MLC current standard method compare identify change study outcome . Audiovisual ( AV ) Biofeedback also use regulate patient ' breathe radiotherapy .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Aged 18 older Has provide write Informed Consent participation trial willing comply study Patients undergoing external beam radiotherapy Northern Sydney Cancer Centre Histologically proven Stage I Non Small Cell Lung Cancer ( NSCLC ) oligometastatic lung metastasis ( 3 less ) . Histological diagnosis obtain clinically indicate . MRI/4DCT prior insertion Calypso beacon Patient must able Varian Calypso beacon place lung ( anticoagulant , must clear Local Medical Officer ( LMO ) cardiologist ) . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Body habitus enable Calypso tracking ( per Calypso Determining Patient 's Localisation Designation &amp; Orientation implantation ) A maximum three metastasis lung nonhaematological malignancy . Multiple metastasis treat separately . Tumour diameter â‰¤ = 5cm Previous highdose thoracic radiotherapy . Less two Calypso beacon implant lung . Calypso beacon space great 9cm less 1cm . Calypso beacon less 19cm outer chest wall Cytotoxic chemotherapy within 3 week commencement treatment , concurrently treatment . Hormonal manipulation agent allowable ( e.g . aromatase inhibitor , selective oestrogen receptor modulators , gonadotropin release hormone receptor modulators ) Targeted agent ( sunitinib , bevacizumab tarceva ) within 7 day commencement treatment , concurrently treatment Women pregnant lactating . Unwilling unable give inform consent Unwilling unable complete quality life questionnaire</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Lung Cancer</keyword>
	<keyword>Stereotactic Ablative Radiotherapy ( SABR )</keyword>
	<keyword>MLC Tracking</keyword>
	<keyword>Radiotherapy</keyword>
</DOC>